^
Association details:
| Biomarker: | TMB-L |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + COM701 (PVRIG inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
640 The combination of COM701 + nivolumab demonstrates preliminary antitumor activity in patients with metastatic breast cancer
Published date:
11/04/2023
Excerpt:
We enrolled 17 patients with MBC, all received COM701 20 mg/kg + nivolumab 480 mg, both IV Q4 week...The combination is well tolerated with no dose-limiting toxicity. Encouraging preliminary antitumor activity with PR and CR reported in heavily pretreated patients with TMB-low MBC.
DOI:
10.1136/jitc-2023-SITC2023.0640
Trial ID:
